CDK-话题@MedSci

#CDK#

85篇内容 | 2944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1435527, encodeId=e1c9143552e03, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, objectType=article, longId=175681, objectId=3cfe1e5681e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cfe1e5681e2, replyNumber=0, likeNumber=65, createdTime=2019-07-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cfe1e5681e2, moduleTitle=诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cfe1e5681e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435526, encodeId=4b4514355264a, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变, objectType=article, longId=175522, objectId=698d1e552260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=698d1e552260, replyNumber=0, likeNumber=87, createdTime=2019-07-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=698d1e552260, moduleTitle=CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=698d1e552260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435525, encodeId=f1a11435525b2, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择, objectType=article, longId=175253, objectId=ba771e52535a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba771e52535a, replyNumber=0, likeNumber=54, createdTime=2019-07-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba771e52535a, moduleTitle=CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba771e52535a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435524, encodeId=27cb1435524c0, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索, objectType=article, longId=170145, objectId=dfb11e0145db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfb11e0145db, replyNumber=0, likeNumber=45, createdTime=2019-06-27, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfb11e0145db, moduleTitle=郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfb11e0145db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435523, encodeId=2cbf143552388, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展, objectType=article, longId=168145, objectId=b59a16814522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b59a16814522, replyNumber=0, likeNumber=72, createdTime=2019-06-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b59a16814522, moduleTitle=CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b59a16814522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435522, encodeId=2b4f143552230, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌, objectType=article, longId=168049, objectId=57f4168049c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f4168049c2, replyNumber=0, likeNumber=79, createdTime=2019-06-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f4168049c2, moduleTitle=新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57f4168049c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435521, encodeId=f9db1435521cb, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, objectType=article, longId=167612, objectId=933416e61276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933416e61276, replyNumber=0, likeNumber=74, createdTime=2019-06-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933416e61276, moduleTitle=2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933416e61276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435520, encodeId=477a14355207a, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, objectType=article, longId=167338, objectId=864316e338a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864316e338a0, replyNumber=0, likeNumber=50, createdTime=2019-06-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864316e338a0, moduleTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864316e338a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435519, encodeId=db0014355194e, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, objectType=article, longId=166117, objectId=2c7916611e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7916611e50, replyNumber=0, likeNumber=56, createdTime=2019-05-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7916611e50, moduleTitle=苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7916611e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435518, encodeId=a12b1435518f6, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多, objectType=article, longId=164704, objectId=fc20164e0485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc20164e0485, replyNumber=0, likeNumber=74, createdTime=2019-04-22, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc20164e0485, moduleTitle=CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc20164e0485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435517, encodeId=6711143551ec6, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, objectType=article, longId=164383, objectId=f363164383a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f363164383a2, replyNumber=0, likeNumber=54, createdTime=2019-04-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f363164383a2, moduleTitle=王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f363164383a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435516, encodeId=dccc1435516e8, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Blood：CDK 6与骨髓增生性肿瘤, objectType=article, longId=164245, objectId=7e4816424526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4816424526, replyNumber=0, likeNumber=135, createdTime=2019-04-15, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4816424526, moduleTitle=Blood：CDK 6与骨髓增生性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4816424526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435515, encodeId=a53e14355150d, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, objectType=article, longId=164062, objectId=b2ee164062f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ee164062f7, replyNumber=0, likeNumber=65, createdTime=2019-04-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ee164062f7, moduleTitle=诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ee164062f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435514, encodeId=c481143551463, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据, objectType=article, longId=161433, objectId=0c111614338f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c111614338f, replyNumber=0, likeNumber=93, createdTime=2019-03-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c111614338f, moduleTitle=2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c111614338f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435513, encodeId=5c721435513d7, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Blood：急性髓系白血病的新靶点——新型CDK9复合物！, objectType=article, longId=158173, objectId=562e1581e3d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=562e1581e3d7, replyNumber=0, likeNumber=67, createdTime=2019-01-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=562e1581e3d7, moduleTitle=Blood：急性髓系白血病的新靶点——新型CDK9复合物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=562e1581e3d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435512, encodeId=a723143551225, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=ARCH PATHOL LAB MED：甲基硫腺苷磷酸化酶与BAP1免疫组化，CDKN2A和NF2荧光原位杂交技术在区分上皮样恶性间皮瘤和上皮细胞增殖中的应用, objectType=article, longId=156978, objectId=6c8e1569e884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c8e1569e884, replyNumber=0, likeNumber=60, createdTime=2018-12-31, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c8e1569e884, moduleTitle=ARCH PATHOL LAB MED：甲基硫腺苷磷酸化酶与BAP1免疫组化，CDKN2A和NF2荧光原位杂交技术在区分上皮样恶性间皮瘤和上皮细胞增殖中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c8e1569e884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435511, encodeId=2abe1435511cb, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, objectType=article, longId=156162, objectId=125715616238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125715616238, replyNumber=0, likeNumber=70, createdTime=2018-12-21, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125715616238, moduleTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125715616238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435510, encodeId=41871435510dc, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值, objectType=article, longId=151214, objectId=deb21512143c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=deb21512143c, replyNumber=0, likeNumber=77, createdTime=2018-10-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=deb21512143c, moduleTitle=徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deb21512143c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435509, encodeId=2c5f14355095e, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂“三兄弟”，谁领风骚, objectType=article, longId=151213, objectId=8256151213d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8256151213d4, replyNumber=0, likeNumber=66, createdTime=2018-10-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8256151213d4, moduleTitle=CDK4/6抑制剂“三兄弟”，谁领风骚, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8256151213d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435508, encodeId=3bf6143550869, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Sci Rep：CDKN2A可以作为肌肉侵入性膀胱癌风险分层和治疗决定的转录组标记, objectType=article, longId=150877, objectId=42721508e76e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42721508e76e, replyNumber=0, likeNumber=64, createdTime=2018-10-14, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42721508e76e, moduleTitle=Sci Rep：CDKN2A可以作为肌肉侵入性膀胱癌风险分层和治疗决定的转录组标记, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42721508e76e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

诺华的新型口服CDK4/6靶向抗癌药Kisqali喜获NICE推荐，用作二线治疗晚期乳腺癌

2019-07-19

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂哌柏西利的上市给HR+乳腺癌的治疗带来改变

2019-07-17

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂哌柏西利成为HR+/HER2-晚期乳腺癌患者的新选择

2019-07-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

郭宇教授：HR+晚期乳腺癌CDK4/6抑制剂进展后的治疗探索

2019-06-27

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂在晚期乳腺癌治疗中的研究进展

2019-06-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌

2019-06-12

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2019ASCO：诺华的CDK4/6抑制剂Kisqali在III期晚期乳腺癌试验中提前到达终点

2019-06-05

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望

2019-06-02

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

苏格兰SMC批准礼来的CDK4/6抑制剂abemaciclib，用于治疗晚期或转移性乳腺癌

2019-05-16

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂联合内分泌一线治疗优势人群获益良多

2019-04-22

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

王涛教授：激素受体阳性晚期乳腺癌一线优先推荐CDK4/6抑制剂联合内分泌治疗

2019-04-18

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Blood：CDK 6与骨髓增生性肿瘤

2019-04-15

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

诺华的CDK4/6靶向性抑制剂Kisqali遭NICE拒绝，用于治疗晚期乳腺癌

2019-04-12

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2019年AACR年会：Syros将展示选择性CDK7抑制剂SY-1365的全新临床前数据

2019-03-02

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Blood：急性髓系白血病的新靶点——新型CDK9复合物！

2019-01-17

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

ARCH PATHOL LAB MED：甲基硫腺苷磷酸化酶与BAP1免疫组化，CDKN2A和NF2荧光原位杂交技术在区分上皮样恶性间皮瘤和上皮细胞增殖中的应用

2018-12-31

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌

2018-12-21

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

徐兵河教授：CDK4/6抑制剂在乳腺癌治疗中的价值

2018-10-18

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂“三兄弟”，谁领风骚

2018-10-18

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Sci Rep：CDKN2A可以作为肌肉侵入性膀胱癌风险分层和治疗决定的转录组标记

2018-10-14

科室
- - 订阅+
  - 更多科室
工具
服务